MONA S. ABDELLATEIF1,*, NAGLAA M. HASSAN2, MAHMOUD M. KAMEL2, YOMNA M. EL-MELIGUI2
Oncology Research, Vol.32, No.3, pp. 577-584, 2024, DOI:10.32604/or.2023.043026
Abstract Background: microRNA-34a (miR-34a) had been reported to have a diagnostic role in acute myeloid leukemia (AML). However, its value in the bone marrow (BM) of AML patients, in addition to its role in response to therapy is still unclear. The current study was designed to assess the diagnostic, prognostic, and predictive significance of miR-34a in the BM of AML patients. Methods: The miR-34a was assessed in BM aspirate of 82 AML patients in relation to 12 normal control subjects using qRT-PCR. The data were assessed for correlation with the relevant clinical criteria, response to therapy, disease-free survival (DFS), and overall… More >